TARRYTOWN, N.Y., May 23 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. will host its Annual Shareholders Meeting on Thursday, May 25, 2006 at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, NY, beginning at 10:00 a.m., Eastern Daylight Time.
Webcast Information
For those shareholders who are unable to attend, Emisphere will webcast the meeting. To access the live broadcast via Internet in listen-only mode, or the subsequently archived recording, please go to the Upcoming Events page in the Investor Relations portion of the Company's web site at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=78250&eventID=1310919
Please visit the site at least five minutes prior to start time for instructions.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere's business strategy is to develop oral forms of drugs that are not currently available or have poor bioavailability in oral form, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of heparin, insulin, salmon calcitonin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world- leading pharmaceutical companies. For further information, please visit our web site, http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission (the "SEC"), including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 16, 2006.
Emisphere Technologies, Inc.CONTACT: Investor Relations: Emisphere Technologies, Inc.,+1-914-785-4742; or Media: Dan Budwick of BMC Communications,+1-212-477-9007, ext. 14, for Emisphere Technologies, Inc.
Web site: http://www.emisphere.com//
